Play all audios:
Access through your institution Buy or subscribe “With any brand new technology, you never know when the world will be ready for it.” So said Paul Boni, an analyst at Punk, Ziegel &
Knoll, in 1998 (as quoted by the _New York Times_), after the US Food and Drug Administration (FDA) approved its first gene-silencing 'antisense therapy', a drug known as Vitravene
(fomivirsen), for the treatment of cytomegalovirus infections in individuals with weakened immune systems. The arrival of Vitravene, a short strand of 21 DNA molecular units that blocks
viral replication, was hailed as a major milestone for the biotech industry and was widely anticipated to usher in a new era of antisense products. But no more came. And by the middle of the
last decade, Isis Pharmaceuticals, the Carlsbad, California–based company behind Vitravene, ended up pulling the therapy from the market because improvements in other antiretrovirals had
effectively eliminated the drug's target market. Boni's cautionary words proved all too prescient. This is a preview of subscription content, access via your institution ACCESS
OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on
SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about
institutional subscriptions * Read our FAQs * Contact customer support Authors * Kevin Jiang View author publications You can also search for this author inPubMed Google Scholar RIGHTS AND
PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Jiang, K. Biotech comes to its 'antisenses' after hard-won drug approval. _Nat Med_ 19, 252 (2013).
https://doi.org/10.1038/nm0313-252 Download citation * Published: 06 March 2013 * Issue Date: March 2013 * DOI: https://doi.org/10.1038/nm0313-252 SHARE THIS ARTICLE Anyone you share the
following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer
Nature SharedIt content-sharing initiative